Fred Mermelstein, Ph.D.
Dr. Mermelstein is the founder of several biotechnology companies and has substantial
management experience with numerous biotech start-up companies. He currently serves
as an Entrepreneur in Residence at Dana Farber Cancer Institute and Director on the
boards of several biopharma companies including Linus Oncology, NX Development Corp.,
Raqia and NXPG Pharmagen.
Dr. Mermelstein served a number of roles at Innovative Drug Delivery Systems (IDDS), rising to role of CEO when the company went public on NASDAQ as Javelin Pharmaceuticals. Prior to Javelin, Dr. Mermelstein served as Director of Venture Capital at Paramount Capital Investments, LLC, a merchant banking and venture capital firm specializing in biotechnology and was founder and served as a director and the Chief Science Officer of PolaRx BioPharmaceuticals, an oncology-based biopharmaceutical company that was acquired by Cell Therapeutics, Inc.
Dr. Mermelstein holds a dual Ph.D. in Pharmacology and Toxicology from Rutgers University and University of Medicine and Dentistry of New Jersey (“UMDNJ”) Robert Wood Johnson Medical School. He completed his post-doctoral training supported by two grant awards, a National Institutes of Health fellowship and a Howard Hughes Medical Institute fellowship in the Department of Biochemistry at UMDNJ Robert Wood Johnson Medical School
|Board of Directors|